Skip to main content

MDx Firm Lumora to Develop Veterinary Dx for Biogal

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a licensing deal to develop tests for veterinary diagnostics company Biogal Galed Labs.

The deal provides Israel-based Biogal access to Lumora's technologies, including BART, or Bioluminescent Assay in Real Time, as well as its expertise in test development, reader technologies, and manufacturing, Lumora said. Initially, Lumora will develop a test for leptospirosis, a zoonotic bacterial infection that is transmitted through urine.

Development of other tests is expected to follow.

"With the leptospirosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline," Laurence Tisi, CEO of Lumora, said in a statement.

Financial terms of the deal were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.